[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

Rhea-AI Filing Summary

PTC Therapeutics chief financial officer Pierre Gravier reported new equity awards. On January 2, 2026, he received 20,000 restricted stock units, which vest in four equal annual installments starting on January 2, 2027. His direct holdings of common stock totaled 92,449 shares after this grant, including shares previously acquired through the company’s employee stock purchase plan.

On the same date, he was also granted a stock option for 50,000 shares of common stock with an exercise price of $76.74 per share and an expiration date of January 1, 2036. This option vests over four years, with 25% vesting on January 2, 2027 and an additional 6.25% of the original grant vesting at the end of each successive three-month period beginning April 2, 2027.

Insights

Equity compensation analyst

Routine multi-year equity grants to the CFO, neutral for shareholders.

The filing shows PTC Therapeutics granted its CFO, Pierre Gravier, 20,000 restricted stock units and a stock option over 50,000 shares on January 2, 2026. The option carries a strike price of $76.74 and expires on January 1, 2036, which is typical for long-term executive incentives.

Both awards vest over four years, with the first tranche on January 2, 2027 and remaining portions vesting annually for RSUs and quarterly for the option thereafter. This structure aligns the CFO’s compensation with multi-year company performance and retention rather than near-term results.

Because these are new grants rather than sales, there is no indication of insider selling pressure here. The awards follow standard vesting schedules and appear consistent with ongoing executive compensation practices, so they are best viewed as routine and not thesis-changing for investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gravier Pierre

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		20,000(1)	A	$0	92,449(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$76.74	01/02/2026		A		50,000		(3)	01/01/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.

2. Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025, and 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025.

3. This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.

	/s/ Avraham S. Adler, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTC Therapeutics (PTCT) disclose for January 2, 2026?

The company reported that its chief financial officer, Pierre Gravier, received 20,000 restricted stock units of common stock and a stock option for 50,000 shares on January 2, 2026.

How do the new restricted stock units for PTCTe28099s CFO vest?

The 20,000 restricted stock units granted on January 2, 2026 vest in four equal installments over four years, starting on January 2, 2027.

What are the key terms of the 50,000-share stock option granted to the PTCT CFO?

The stock option covers 50,000 shares of common stock with an exercise price of $76.74 per share and an expiration date of January 1, 2036. It vests over four years, with 25% vesting on January 2, 2027 and 6.25% of the original grant vesting at the end of each three-month period starting April 2, 2027.

How many PTC Therapeutics (PTCT) common shares did the CFO own after the reported transaction?

Following the reported grants, Pierre Gravier directly beneficially owned 92,449 shares of PTC Therapeutics common stock.

Does the Form 4 indicate that the PTCT CFO sold any shares?

No. The transactions reported for January 2, 2026 are acquisitions of restricted stock units and stock options, not sales of existing shares.

What role does Pierre Gravier hold at PTC Therapeutics (PTCT)?

Pierre Gravier is identified in the filing as an officer of PTC Therapeutics, serving as the companye28099s chief financial officer.

Are any of the PTCT CFOe28099s shares from the employee stock purchase plan mentioned?

Yes. The filing notes that his holdings include 272 shares acquired under the employee stock purchase plan for the period ended June 30, 2025 and 257 shares for the period ended December 31, 2025.